Allogeneic NK cells generated from cord blood as universal treatment for cervical cancer enabled by HLA independent killing mechanisms.
John P. Veluchamy(Cancer Center Amsterdam), Tanja D. de Gruijl(Dutch Cancer Society), A. Marijne Heeren(Academic Center for Dentistry Amsterdam), Jan Spanholtz(AIMM Therapeutics (Netherlands)), Gemma G. Kenter(European Organisation for Research and Treatment of Cancer), Henk M.W. Verheul(Erasmus MC Cancer Institute), Ekaterina S. Jordanova(Centrum voor Gynaecologische Oncologie Amsterdam), Jaap D. H. van Eendenburg(Leiden University Medical Center), Daniëlle A.M. Heideman(University Medical Center Groningen)
Cited by 0
Related Papers
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
|New England Journal of Medicine|2012|5.5k
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
|Journal of Clinical Oncology|2021|795
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|582
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
|Nature reviews. Cancer|2007|502